Jiayuan Technology: granted 1975300 restricted shares to 163 incentive objects

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Unpacking China | Key Chinese Firms to Watch This Week （20/09/2026-26/09/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Beyond the Car: China’s Next Wave of Intelligent Hardware

The next chapter for intelligent vehicles is unfolding both inside and beyond the car.

Moonshot AI’s Kimi K3 Joins Amazon Bedrock as Overseas Revenue-Sharing Model Takes Shape

Amazon Web Services announced on September 18 that Kimi K3, developed by China’s Moonshot AI（月之暗面）, is available on Amazon Bedrock, expanding the model’s access to enterprise customers through AWS’s managed AI platform. On September 21, National Business Daily reported that Moonshot had confirmed an overseas cloud revenue-sharing arrangement, adding a commercial dimension to the launch. The financial terms remain undisclosed.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.